Cargando…

Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review

Motor complications in Parkinson’s disease (PD) result from the short half-life and irregular plasma fluctuations of oral levodopa. When strategies of providing more continuous dopaminergic stimulation by adjusting oral medication fail, patients may be candidates for one of three device-aided therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Volkmann, Jens, Albanese, Alberto, Antonini, Angelo, Chaudhuri, K. Ray, Clarke, Carl E., de Bie, Rob M. A., Deuschl, Günther, Eggert, Karla, Houeto, Jean-Luc, Kulisevsky, Jaime, Nyholm, Dag, Odin, Per, Østergaard, Karen, Poewe, Werner, Pollak, Pierre, Rabey, Jose Martin, Rascol, Olivier, Ruzicka, Evzen, Samuel, Michael, Speelman, Hans, Sydow, Olof, Valldeoriola, Francesc, van der Linden, Chris, Oertel, Wolfgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825542/ https://www.ncbi.nlm.nih.gov/pubmed/23287972 http://dx.doi.org/10.1007/s00415-012-6798-6

Ejemplares similares

Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus
por: Stocchi, Fabrizio, et al.
Publicado: (2022)

The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson’s disease
por: Eggington, Simon, et al.
Publicado: (2013)

A Loud Auditory Stimulus Overcomes Voluntary Movement Limitation in Cervical Dystonia
por: Serranová, Tereza, et al.
Publicado: (2012)

Patient-centred management of Parkinson's disease
por: Grimes, David, et al.
Publicado: (2020)

Levodopa–carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry
por: Poewe, Werner, et al.
Publicado: (2019)

Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson’s disease
por: Odin, Per, et al.
Publicado: (2018)

Close relationships in Parkinson´s disease patients with device‐aided therapy
por: Scharfenort, Monica, et al.
Publicado: (2021)

Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial
por: Chaudhuri, K. Ray, et al.
Publicado: (2022)

Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial
por: Ferreira, Joaquim J., et al.
Publicado: (2022)

Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
por: Ferreira, Joaquim J., et al.
Publicado: (2022)

Erratum: Pagonabarraga, J.; et al. A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice. Brain Sci. 2020, 10, 176
por: Pagonabarraga, Javier, et al.
Publicado: (2020)

A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice
por: Pagonabarraga, Javier, et al.
Publicado: (2020)

Cirugía de los trastornos del movimiento
por: Valldeoriola Serra, Francesc
Publicado: (2007)

Burden of non‐motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa‐carbidopa intestinal gel
por: Ray Chaudhuri, K., et al.
Publicado: (2018)

Eduard Gamper (1887–1938): cases and accidents
por: Ruzicka, Evzen, et al.
Publicado: (2021)

The Category of Conventional Physiotherapy: The Case of Parkinson’s Disease Guidelines
por: Hoskovcová, Martina, et al.
Publicado: (2022)

The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
por: Rocha, José-Francisco, et al.
Publicado: (2021)

The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II
por: Rocha, José-Francisco, et al.
Publicado: (2022)

Long‐term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open‐label extensions
por: Ferreira, J. J., et al.
Publicado: (2019)

Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?
por: Catalán, Maria José, et al.
Publicado: (2017)

Weight Gain Is Associated with Medial Contact Site of Subthalamic Stimulation in Parkinson's Disease
por: Růžička, Filip, et al.
Publicado: (2012)

Automatic Evaluation of Speech Rhythm Instability and Acceleration in Dysarthrias Associated with Basal Ganglia Dysfunction
por: Rusz, Jan, et al.
Publicado: (2015)

Predictors of Response for “Off” Time Improvement With Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis of the GLORIA Registry
por: Poewe, Werner, et al.
Publicado: (2020)

Emergencies and critical issues in Parkinson’s disease
por: Simonet, Cristina, et al.
Publicado: (2020)

How I do it — asleep DBS placement for Parkinson’s disease
por: Roldan, Pedro, et al.
Publicado: (2023)

Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease
por: Bergquist, Filip, et al.
Publicado: (2022)

A survey of lifestyle factors in dystonia
por: Söderlund, Jacob, et al.
Publicado: (2020)

Optimizing Treatment of Parkinson’s Disease
por: Nyholm, Dag, et al.
Publicado: (2022)

The natural history of multiple system atrophy: a prospective European cohort study
por: Wenning, Gregor K, et al.
Publicado: (2013)

Effects of DBS in parkinsonian patients depend on the structural integrity of frontal cortex
por: Muthuraman, Muthuraman, et al.
Publicado: (2017)

Distinct patterns of speech disorder in early-onset and late-onset de-novo Parkinson’s disease
por: Rusz, Jan, et al.
Publicado: (2021)

Short-term effect of dopaminergic medication on speech in early-stage Parkinson’s disease
por: Tykalova, Tereza, et al.
Publicado: (2022)

Development of new levodopa treatment strategies in Parkinson’s disease—from bedside to bench to bedside
por: Aquilonius, Sten-Magnus, et al.
Publicado: (2017)

Effects of Helicobacter pylori on Levodopa Pharmacokinetics
por: Nyholm, Dag, et al.
Publicado: (2021)

Levodopa–entacapone–carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-world experience and practical guidance
por: Nyholm, Dag, et al.
Publicado: (2022)

Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety
por: Poewe, Werner, et al.
Publicado: (2019)

Frequency-phase analysis of resting-state functional MRI
por: Goelman, Gadi, et al.
Publicado: (2017)

Corrigendum: Frequency-phase analysis of resting-state functional MRI
por: Goelman, Gadi, et al.
Publicado: (2017)

Separate neural representations of depression, anxiety and apathy in Parkinson’s disease
por: Dan, Rotem, et al.
Publicado: (2017)

Moving towards Integrated and Personalized Care in Parkinson’s Disease: A Framework Proposal for Training Parkinson Nurses
por: van Munster, Marlena, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s9ltl86amm1qjirnb8ar0crnfp